Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled RVT-1601 for Persistent Cough in IPF
NCT03864328Phase 2Terminated
- Sponsor
- Respivant Sciences
- Start
- Mar 2019
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial of RVT-1601 in idiopathic pulmonary fibrosis (IPF), sponsored by Respivant Sciences. Primary endpoint: Change in 24-hour average cough count at 12 weeks. Started Mar 2019; status: terminated.
02
Drugs
RVT-1601
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT03864328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03864328.